ArticleThe oncologist2025
Retrospective study of elderly patients with advanced ovarian cancer who did not undergo surgery.
Article in The oncologist, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the clinical outcomes of elderly patients with advanced ovarian cancer who did not undergo surgery and received chemotherapy with or without maintenance therapy.
methodsWe retrospectively analyzed the clinical data of 15 patients with advanced high-grade serous ovarian cancer who were treated at our hospital between 2018 and 2023. These patients either had multiple comorbidities or refused surgery. Data collected included patient demographics, treatment regimens, chemotherapy cycles, clinical response, progression-free survival (PFS), and overall survival (OS).
resultsThe median age of the patients was 73 years (range, 50-86 years). Fourteen patients received platinum-based chemotherapy combined with paclitaxel or liposomal doxorubicin, with or without bevacizumab, for 3 to 6 cycles. Twelve patients who achieved disease control received PARP inhibitor maintenance therapy. The overall response rate (ORR) was 80.0%, or 12/15 patients achieved partial response (PR); nobody achieved complete response. The disease control rate (DCR) was 100%. The median PFS1 was 19.0 months (95% CI, 11.85-26.15), and the median PFS2 was 10 months. The 3-year OS rate was 65.2%, with a median OS of 57.0 months (95% CI, 13.00-100.99).
conclusionsChemotherapy with or without bevacizumab, followed by PARP inhibitor maintenance therapy, is a viable alternative for elderly or surgically ineligible patients with advanced ovarian cancer. The findings of this study should be considered exploratory and require validation through large-scale studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.